| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations.
|
Pain
|
2013
|
2.58
|
|
2
|
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.
|
Pain
|
2013
|
1.89
|
|
3
|
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations.
|
Pain
|
2012
|
1.88
|
|
4
|
Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system.
|
Pain
|
2016
|
1.39
|
|
5
|
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives.
|
Curr Med Res Opin
|
2013
|
1.02
|
|
6
|
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.
|
Pain
|
2012
|
0.95
|
|
7
|
Evaluation of the depth and duration of anesthesia from heated lidocaine/tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers.
|
Reg Anesth Pain Med
|
2010
|
0.92
|
|
8
|
Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations.
|
Pain
|
2016
|
0.82
|
|
9
|
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.
|
Pain
|
2016
|
0.81
|
|
10
|
A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain.
|
Pain
|
2015
|
0.81
|
|
11
|
Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations.
|
Pain
|
2015
|
0.79
|
|
12
|
Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options.
|
Curr Med Res Opin
|
2014
|
0.79
|
|
13
|
The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.
|
J Pain
|
2017
|
0.75
|